Adaptimmune

Adaptimmune and TCR2 Agree Merger

Clinical stage biotechs Adaptimmune and TCR2 Therapeutics have agreed to merge, forming what they said would be a “preeminent cell therapy company focused on creating solid tumors” with projected sales of about $27 billion by 2026.

News

Adaptimmune Strengthens Management Team with Key Executive Hires

News

Adaptimmune in Cancer Collaboration With GlaxoSmithKline

Top-Feature

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

JULABO GmbH

When Every Temperature Change Determines the Process

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

INOSIM GmbH

Predictive Simulation in Pharma Production

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.